ReshmaRangwalaMD
Internal Medicine • Saint Louis, MOHospital Medicine/Hospitalist, Hematology/Oncology
Physician
Are you Dr. Rangwala?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Barnes Jewish Hospital Plz
Saint Louis, MO 63110Phone+1 314-362-1700Fax+1 314-362-9878
Summary
- Dr. Reshma Rangwala, MD is an internist in Saint Louis, Missouri.
Publications & Presentations
PubMed
- 67 citationsTisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.David S. Hong, Nicole Concin, Ignace Vergote, Johann S. de Bono, Brian M. Slomovitz
Clinical Cancer Research. 2020-03-15 - 130 citationsTisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trialJohann S. de Bono, Nicole Concin, David S. Hong, Fiona C Thistlethwaite, Jean-Pascal Machiels
The Lancet. Oncology. 2019-03-01 - 289 citationsPhase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanomaReshma Rangwala, Robert D. Leone, Yunyoung C. Chang, Leslie A. Fecher, Lynn M. Schuchter
Autophagy. 2014-05-20
Press Mentions
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisOctober 31st, 2024- Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDSMay 3rd, 2023
- Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 ObjectivesJanuary 9th, 2023
- Join now to see all
